Bristol-Myers Squibb Company is set to gain access to new targets for the development of checkpoint inhibitors against cancer under a licensing deal with Five Prime Therapeutics Inc carrying an upfront payment of $20 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
